Metformin

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Metformin

A biguanide that lowers blood glucose by reducing hepatic glucose output, first-line for type 2 diabetes.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved.

Metformin is a biguanide oral medication that lowers blood glucose primarily by reducing hepatic glucose production and improving peripheral insulin sensitivity. It is approved by the FDA as an adjunct to diet and exercise for improving glycemic control in adults and in pediatric patients with type 2 diabetes, and it remains the most widely prescribed first-line oral diabetes medication worldwide. Decades of clinical trial and epidemiological data cover its cardiovascular, renal, and metabolic effects.

Benefits reported in the imported source

• First-line oral therapy for type 2 diabetes in adults and in pediatric patients ten and older.
• One of the most extensively studied oral diabetes medications, with decades of clinical trial and real-world outcome data.
• Labeled indication is as an adjunct to diet and exercise rather than a replacement for lifestyle management.

Risks and limits

• Carries a boxed warning for lactic acidosis, a rare but serious adverse reaction more likely with renal impairment, hepatic impairment, or excessive alcohol intake.
• Labeling notes potential reduction in vitamin B12 levels with long-term use.
• Gastrointestinal adverse effects such as nausea and diarrhea are commonly reported.

Source bottom line: Metformin is an FDA-approved, extensively studied first-line oral medication for type 2 diabetes, labeled with a boxed warning for lactic acidosis and periodic monitoring requirements.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Pharmacokinetic context

Historical half-life estimate: 6.2 hours. FDA label, Glumetza: plasma half-life about 6.2 hours (whole-blood/erythrocyte half-life is longer, about 17.6 hours, due to red-cell partitioning) Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Metformin hydrochloride tablet label — DailyMed